Edwards Keeps TAVR Going During COVID-19 Surge

Fourth-quarter sales of Edwards Sapien transcatheter aortic valve systems grew 2% year-over-year overall, despite the intense challenges created by COVID-19.

Post pandemic vision; economic outlook after Coronavirus COVID-19 crisis concept
• Source: shutterstock.com

Edwards Lifesciences expects transcatheter aortic valve replacement (TAVR) procedure volumes to drop in the first quarter of 2021 before “normalizing” by the middle of 2021 as the pandemic begins to subside.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

More from Device Area